Q3 2025 · 13F-HR
Lion Point Capital, LPholdings as filed
Filed 2025-11-14 · accession 0001013594-25-001425
$17.6M
Reported value
27
Positions
2025-09-30
Period end
The Brief · Lion Point Capital, LP · Q3 2025
AI · grounded in 13F
Lion Point Capital, LP established a new position in ROYALTY PHARMA PLC valued at $754,992. The fund also opened new stakes in MLTX for $483,975 and KURA for $407,100. On the sell side, the fund closed its position in MERSANA THERAPEUTICS INC and reduced its holdings in ARDX by 51.48%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $1.5M | 8.40% | 39,000 | Common | SOLE |
| 59935V107 | MIST | MILESTONE PHARMACEUTICALS IN | $1.3M | 7.48% | 658,553 | Common | SOLE |
| 31447P100 | FENC | FENNEC PHARMACEUTICALS INC | $1.2M | 6.54% | 123,000 | Common | SOLE |
| 471871202 | JSPR | JASPER THERAPEUTICS INC | $948,568 | 5.39% | 398,558 | Common | SOLE |
| G29687103 | AVDL | AVADEL PHARMACEUTICALS PLC | $911,619 | 5.18% | 59,700 | Common | SOLE |
| G52694109 | KNSA | KINIKSA PHARMACEUTICALS INTL | $908,622 | 5.16% | 23,400 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $900,063 | 5.11% | 6,250 | Common | SOLE |
| 039697107 | ARDX | ARDELYX INC | $896,753 | 5.09% | 162,750 | Common | SOLE |
| 08205P209 | BNTC | BENITEC BIOPHARMA INC | $869,860 | 4.94% | 62,000 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $846,175 | 4.81% | 55,000 | Common | SOLE |
| G7709Q104 | RPRX | ROYALTY PHARMA PLC | $754,992 | 4.29% | 21,400 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $700,448 | 3.98% | 10,600 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $690,802 | 3.92% | 13,300 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $685,000 | 3.89% | 500,000 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $665,405 | 3.78% | 35,300 | Common | SOLE |
| 75901B107 | RGNX | REGENXBIO INC | $557,288 | 3.17% | 57,750 | Common | SOLE |
| 81750R201 | MCRB | SERES THERAPEUTICS INC | $522,135 | 2.97% | 27,138 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $483,975 | 2.75% | 67,500 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $407,100 | 2.31% | 46,000 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $340,727 | 1.94% | 22,700 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $332,340 | 1.89% | 58,000 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $302,100 | 1.72% | 5,700 | Common | SOLE |
| 23954D109 | DAWNGBX | DAY ONE BIOPHARMACEUTICALS I | $296,100 | 1.68% | 42,000 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $280,360 | 1.59% | 86,000 | Common | SOLE |
| 59045L205 | MRSN | MERSANA THERAPEUTICS INC | $199,898 | 1.14% | 25,760 | Common | SOLE |
| 44486Q103 | HUMA | HUMACYTE INC | $145,290 | 0.83% | 83,500 | Common | SOLE |
| 85209E208 | SPRB | SPRUCE BIOSCIENCES INC | $8,950 | 0.05% | 1,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.